Practical Pearls for Community Oncologists Treating ROS1-Positive NSCLC
Oncology experts provide guidance for community doctors treating ROS1-positive non-small cell lung cancer, emphasizing the importance of second opinions and careful treatment selection. They warn against relying solely on alphabetical drug lists and highlight the need for patient-specific considerations.
Why it matters
This advice helps community oncologists navigate complex treatment landscapes to improve patient outcomes in precision medicine.
Martin Dietrich, MD, PhD, tells community oncologists to build in access to second opinions, often by telemedicine, and says he would rather be slow and right than fast and wrong, because a less effective first choice drives resistance that later agents cannot fully recover.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in